Aug 18,2014

Globavir Bioscience's recent announcement regarding the development of its lead therapeutic candidate, GBV006, has drawn attention from several media outlets, including MarketWatch, Bloomberg, and other outlets. GBV006, which is a combination of two approved drugs and has demonstrated efficacy in models of Ebola infection, has the potential to be rapidly distributed in combatting the current outbreak in Africa. As Globavir's CEO, Dr. Shalabh Gupta said, "By repurposing a combination of approved drugs to treat Ebola virus, Globavir has the potential to overcome many hurdles regarding safety and supply of experimental therapies. We hope to quickly form partnerships to distribute this potentially life-saving drug to those who need it most."